Oppenheimer maintained an Outperform rating on Teva Pharma (NYSE: TEVA), and cut the price target to $72.00 (from $77.00), after ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE